CRESCENT BIOPHARMA INC
CBIONASDAQ🏆 #2839 by market capEarnings Nov 4US Equity
$14.09▲ $0.57 (+4.25%)
Market closed · at closeTrack CBIO
Get earnings, price moves & breaking news on Telegram
24h▲ 4.3%
7d▲ 9.9%
14d▲ 19.5%
30d▼ 3.7%
ytd▲ 19.3%
1y▲ 12.2%
🏦Market Cap
$523M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
42.2x
Expensive
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $13.57 – $14.78
- 52-Week Range
- $8.72 – $27.41
- Volume (shares)
- 23,057
- Avg Volume (shares)
- —
- Shares Outstanding
- 37.1M
- Next Earnings
- 2026-11-04
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 42.2x
- EPS (TTM)
- $-7.41
- Dividend Yield
- —
- Dilution (1yr)
- +3028.0%
CRESCENT BIOPHARMA INC
CBIOFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$11M▲ +0.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$153M▲ +205.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$144M▲ +364.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
20.2M▲ +3028.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$212M▲ +$201M YoY
StockOtter · stockotter.spaceAbout CRESCENT BIOPHARMA INC
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
14 analysts
Strong Buy5
Buy7
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.